Ashley Chan

Natural language processing models could help streamline processes within clinical settings.

Darren Pan, MD, highlighted key sequencing strategies for T-cell redirection therapy in relapsed/refractory multiple myeloma.

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.

Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.

Cyrus M. Khan, MD, discusses the role of second-generation BTK inhibitors and their implications for clinical practice in the CLL treatment paradigm.

Hans Hammers, MD, PhD, discusses the efficacy, safety, and clinical utilization of IO/IO and IO/TKI combinations in advanced clear-cell RCC.

Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Apalutamide plus carotuximab has been demonstrated to be well tolerated in patients with metastatic castration-resistant prostate cancer

Breelyn Wilky, MD, discusses the importance of recognizing GIST Awareness Day and research towards moving the needle in the GIST treatment paradigm.

Lydia Scarfò, MD, details the early efficacy and safety profile of BTK degrader BGB-16673 for the treatment of patients with relapsed/refractory CLL/SLL.

The European Commission has approved tislelizumab plus gemcitabine/cisplatin for adults with recurrent or metastatic nasopharyngeal carcinoma.

Peter Voorhees, MD, highlights 5-year follow-up data from the CARTITUDE-1 trial evaluating cilta-cel in relapsed/refractory multiple myeloma.

A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.

Ajai Chari, MD, expands on areas of uncertainty in multiple myeloma after his presentation at the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Zidesamtinib, a selective ROS1 inhibitor, was well tolerated and showed antitumor activity in pretreated, advanced ROS1-positive NSCLC.

As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.

Andrew Kuykendall, MD, discusses the utility of rusfertide in reducing therapeutic phlebotomy eligibility in patients with polycythemia vera.

Naomi B. Haas, MD, delves into the KEYNOTE-564 trial and highlights the role of adjuvant pembrolizumab in clear cell renal cell carcinoma.

Gecacitinib, a dual JAK/ACVR1 inhibitor, showed spleen volume, symptom and anemia improvements in patients with myelofibrosis.

Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.

The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.

The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

Martin E. Gutierrez, MD, discusses steps towards a continuous shift in both the NSCLC and SCLC treatment paradigms, based on trials presented at ASCO 2025.

Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Health Canada has approved a quizartinib-based regimen for the treatment of patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.